Wedbush Maintains Outperform Rating on Aclaris Therapeutics, $8 Target
Wedbush maintained its Outperform rating and $8.00 price target. The target implies 111.1% upside from the October 27 close of $3.79.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.